Finance

Lists
Why is MCRB up 3,04%?
Dive Deeper
MCRB:NASDAQ
Seres Therapeutics Inc
US$2,71
+3,04%
(+0,080) 1D
US$2,79
+3,12% (+0,085)
After hours
Closed: 9 ຕ.ລ., 16 ໂມງ 0 ນາທີ 01 ວິນາທີ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MCRB...
Open
US$2,65
High
US$2,75
Low
US$2,58
Mkt. cap
26,94 ລ້ານ
Avg. vol.
68,95 ພັນ
Volume
79,41 ພັນ
52-wk high
US$29,98
52-wk low
US$2,42
EPS
US$-2,33
Beta
0,31
Shares outstanding
9,94 ລ້ານ
No. of employees
66
Open
US$2,65
High
US$2,75
Low
US$2,58
Mkt. cap
26,94 ລ້ານ
Avg. vol.
68,95 ພັນ
Volume
79,41 ພັນ
52-wk high
US$29,98
52-wk low
US$2,42
EPS
US$-2,33
Beta
0,31
Shares outstanding
9,94 ລ້ານ
No. of employees
66
News stories
From web sources and news partners
About Seres Therapeutics Inc
CEOEric Shaff
Employees66
Founded2010
Headquarters-
SectorBiotechnology
Analyst ratings
Based on 2 analysts giving stock ratings to MCRB in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for MCRB in the last 3 months.
Highest
Current US$2,71
US$22,00 (+711,81%)
Average
US$17,00 (+527,31%)
Lowest
US$12,00 (+342,80%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Newman
Canaccord Genuity
Buy
Maintained
US$22,00
+711,8%
08/06/2026
Matthew Keller
H.C. Wainwright
Buy
Reiterated
US$12,00
+342,8%
08/05/2026
Edward Tenthoff
Piper Sandler
Hold
Maintained
US$20,00
+638%
02/13/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
11/05/2025
Last report
5 ສ.ຫ. 2026
Fiscal period
Q2 2026
US$1,07 / US$-2,18
+148,77%beat
Revenue / Est. (USD)
736,00 ພັນ / 358,00 ພັນ
+105,59%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
351,00 ພັນ
438,00 ພັນ
358,00 ພັນ
736,00 ພັນ
Cost of goods sold
13,35 ລ້ານ
12,28 ລ້ານ
13,20 ລ້ານ
9,14 ລ້ານ
Cost of revenue
13,35 ລ້ານ
12,28 ລ້ານ
13,20 ລ້ານ
9,14 ລ້ານ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,48 ລ້ານ
7,54 ລ້ານ
8,07 ລ້ານ
7,06 ລ້ານ
Operating expense
9,48 ລ້ານ
7,54 ລ້ານ
8,07 ລ້ານ
7,06 ລ້ານ
Total operating expenses
22,83 ລ້ານ
19,82 ລ້ານ
21,26 ລ້ານ
16,20 ລ້ານ
Operating income
-22,48 ລ້ານ
-19,38 ລ້ານ
-20,91 ລ້ານ
-15,47 ລ້ານ
Other non operating income
2,84 ລ້ານ
2,33 ລ້ານ
669,00 ພັນ
673,00 ພັນ
EBT including unusual items
8,20 ລ້ານ
-15,34 ລ້ານ
-19,91 ລ້ານ
4,58 ລ້ານ
EBT excluding unusual items
-19,02 ລ້ານ
-16,60 ລ້ານ
-19,91 ລ້ານ
-14,61 ລ້ານ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
8,20 ລ້ານ
-15,34 ລ້ານ
-19,91 ລ້ານ
4,58 ລ້ານ
Net profit margin
2.337,32%
-3.501,14%
-5.562,29%
622,42%
Earnings per share
0,94
-1,76
-2,08
1,07
Interest and investment income
618,00 ພັນ
445,00 ພັນ
325,00 ພັນ
181,00 ພັນ
Interest expense
-
-
-
-
Net interest expenses
618,00 ພັນ
445,00 ພັນ
325,00 ພັນ
181,00 ພັນ
Depreciation and amortization charges
-
-
-
-
EBITDA
-21,43 ລ້ານ
-18,42 ລ້ານ
-20,13 ລ້ານ
-14,80 ລ້ານ
Gain or loss from assets sale
-
-192,00 ພັນ
-
139,00 ພັນ
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
ແອັບຂອງ Google